Parameter
| Biomarker | PD-L1 | Full name | Programmed Death-Ligand 1 | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Prediction, Pharmacodynamics/Response |
| Disease | Meningioma | Disease Subtypes | / | ||
| Organ | Brain, Meninges | Test Sample / Technology Platform | Tumor Tissue (Immunohistochemistry) | ||
| Pathobiological Mechanisms | An immune checkpoint molecule that inhibits the anti-tumor activity of T cells. | ||||
| Clinical Availability Status | Research Stage | ||||
| Notes and Dynamics | Patients with high expression may be sensitive to PD-1/PD-L1 inhibitors, and related clinical trials are ongoing. | ||||